ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03108196
Recruitment Status : Enrolling by invitation
First Posted : April 11, 2017
Last Update Posted : April 10, 2018
Sponsor:
Collaborators:
Sun Yat-sen University
The Third Affiliated Hospital of Southern Medical University
Fourth Affiliated Hospital of Guangxi Medical University
Information provided by (Responsible Party):
Zhujiang Hospital

Brief Summary:

Bladder cancer is a common malignant tumor of the urinary system, radical resection plus urinary diversion is the first choice of treatment for muscle invasive bladder cancer. Urinary diversion of surgical options related to patient' survival and quality of life.

In 1988, Hautmann firstly reported an orthotopic urinary diversion method: Hautmann neobladder. As the urine can be controlled from the original urethra, the patient's quality of life has been greatly improved, so the new bladder surgery gradually accepted and welcomed by urologists and patients. However, in order to achieve low-pressure and large-volume storage capacity of the urine reservoir, the 40-70cm long interception of terminal ileum need to be detubularized. Only after split, folded, re-stitched and a series of treatment, the intestinal can be used. Such complicated procedures make so many urologists give it up. In addition, the interception of the long ileum may lead to reduced absorption of vitamin B12 which caused anemia, metabolic acidosis, intestinal dysfunction. Not only that, as time goes by, this kind of neobladder will be unlimited expansion and resulting in a serious increase in residual urine volume, hydronephrosis, or even the occurrence of neobladder spontaneous rupture.

In 2000, professor Chunxiao Liu invented "detaenial sigmoid neobladder", this surgical method overset the traditional intestinal detubularization approach, which detached the serosal layer with smooth muscle from the bowel without split it. This kind of neobladder is easier to construct and have less impact on intestinal function. So far, it has been implemented for more than 600 cases in Zhujiang hospital, the age of patients range from 9 months (bladder rhabdomyosarcoma) to 84 years old.

So far as now, no multicenter prospective clinical study on orthotopic urinary diversion has been performed worldwide, neither the head-to-head studies on detaenial sigmoid neobladder and ileal neobladder.

Our project is going to perform a multicenter randomized controlled trial for these two neobladder methods and look forward to assess the safety and efficacy of these two procedures which provide an objective basis for the patients undergoing orthotopic urinary diversion in the future.


Condition or disease Intervention/treatment Phase
Bladder Cancer Urinary Diversion Procedure: sigmoid Procedure: ileal Not Applicable

Detailed Description:

Surgical technique for Hautmann ileal neobladder: A 70-cm portion of terminal ileum is selected and incised on the antimesenteric border. The ileum is arranged into an M or W configuration with the four limbs sutured to one another. After a buttonhole of ileum is removed on an antimesenteric portion of the ileum, the urethral anastomosis is performed. The ureteral anastomoses are performed using a Le Duc technique or direct implantation, are stented, and the reservoir is then closed in a side-to-side manner. As an alternative, the two ends of the W may be left slightly longer as a short chimney on either side for implantation of the ureters.

Surgical technique for detaenial sigmoid neobladder: After radical cystectomy, the sigmoid was brought out from a midline incision in the lower abdomen and a 15 to 25 cm segment was isolated. Intestinal continuity was restored using a circular stapler. Omental and free taeniae, and the serosal layer were incised deeply as far as the submucosal layer until the plane between smooth muscle and the submucosal layer could be identified clearly by scalpel dissection. The serosal layer with smooth muscle was then detached from the submucosal layer and removed continuously without difficulty. During this time, the operator could insert the finger in the sigmoid lumen and lift the sigmoid wall up for accurate dissection. Only the mucosal and submucosal layers were preserved. Approximately 2 to 3 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The detaenial sigmoid was irrigated repeatedly by dilute iodine solution to eliminate impurities. Its capacity for enlargement and leak tightness were assessed at the end by filling with 300 to 400 ml iodine solution. Residual taeniae were identified and incised during this filling phase. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel with 4-zero poly glactin at the two ends of sigmoid. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. Each stent was passed through the sigmoid wall and exteriorized. The two ends of the sigmoid were closed by 2-zero polyglactin with the embedded seromuscular layer. The central portion of the sigmoid was incised and a 22Fr 3-way catheter was inserted in neobladder. The neobladder was anastomosed to the urethra with 2-zero polyglactin.

Followup: Each patient was evaluated at 3-month intervals for 1 year, at 6-month intervals for 2 to 5 years. Renal ultrasound, biochemical examination and urine culture were done every 3 to 6 months. Pelvic computerized tomography and retro-cystogram were performed 6 months postoperatively and annually thereafter. Urodynamic investigation and cystoscopic examination were done annually.

Postoperative complications were classified as early (90 days or less) and late (greater than 90 days). Early and late complications were subdivided into those related and not related to the neobladder. Complication grade was classified according to the Clavien-Dindo system. Major complications were defined as grade III or higher. Daytime and nighttime continence levels were recorded postoperatively at patient interview. Continence was defined as complete if the patient was dry without a pad, satisfactory if no more than 1 pad was required and poor if the patient used more than 1 pad during the day or night.

End points: The primary end point was change in renal function from baseline to 3 years. Secondary end points included changes in renal function from baseline to 6, 12 and 24 months, reduction in eGFR 10 ml/minute/1.73 m2 or greater, early (less than 90 days) and late (90 days to 3 years) complications, urinary tract infection that was symptomatic or was treated, any surgical re-intervention or urinary diversion related surgical re-intervention defined as an open or endoscopic procedure under anesthesia, cancer recurrence and overall survival. Renal function was assessed using the CKD-EPI equation. Complications were analyzed and graded by a blinded adjudicator using the modified Clavien complication grading system.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Superiority verification based on the ileal neobladder
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Randomized Controlled Study to Compare the Safety and Efficacy of Detaenial Sigmoid Neobladder and Hautmann Ileal Neobladder in Patients With Bladder Cancer
Actual Study Start Date : May 1, 2017
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : September 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: sigmoid
Use 15 cm detaenial sigmoid colon to reconstructed a "U" shape neobladder after radical cystectomy.
Procedure: sigmoid
The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.

Experimental: ileal
Use 70 cm distal ileal segment to reconstructed a "spherical" shape neobladder after radical cystectomy.
Procedure: ileal
The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped flap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.




Primary Outcome Measures :
  1. Post void residual volume of neobladder [ Time Frame: the 36th month ]
    Residual urine volume after spontaneous urination with urinary diversion in the 36th month


Secondary Outcome Measures :
  1. Time cost [ Time Frame: 24 hour ]
    Time consuming of neobladder construction

  2. EBL [ Time Frame: 24 hour ]
    Estimated blood loss

  3. Short term complications [ Time Frame: 90 day postoperative ]
    Complications which happened during 90 day postoperative



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Bladder carcinoma in situ, include CIS and T1G3 tumor, muscle invasive bladder cancer(T2/T3N0-1M0)
  2. Recurrent bladder cancer
  3. Other conditions that have been approved by a urologist for indications for new bladder surgery
  4. Had been received intravesical chemotherapy, intra-arterial infusion chemotherapy or systemic chemotherapy in the past.
  5. Voluntarily signed the informed consent -

Exclusion Criteria:

  1. Preoperative serum creatinine more than 2.26mg/dl(Or 200μmol/L)
  2. Cancer invaded urethral (confirmed by the pathology)
  3. Non - bladder cancer patients underwent neobladder
  4. A history of other malignant tumors within five years
  5. Ileum / sigmoid chronic inflammation, like ulcerative colitis or intestinal tuberculosis, and so on.
  6. Other conditions that have been approved by a urologist for not suitable for new bladder surgery


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03108196


Locations
China, Guangdong
Zhujiang Hospital
Guangzhou, Guangdong, China, 510282
Sponsors and Collaborators
Zhujiang Hospital
Sun Yat-sen University
The Third Affiliated Hospital of Southern Medical University
Fourth Affiliated Hospital of Guangxi Medical University
Investigators
Principal Investigator: Qian Wang, doctor Zhujiang Hospital

Publications of Results:
Other Publications:
Responsible Party: Zhujiang Hospital
ClinicalTrials.gov Identifier: NCT03108196     History of Changes
Other Study ID Numbers: LC2016PY030
First Posted: April 11, 2017    Key Record Dates
Last Update Posted: April 10, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All released data will be available for other researchers.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Zhujiang Hospital:
bladder cancer, neobladder, detaenial sigmoid, ileal

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases